186 related articles for article (PubMed ID: 33719152)
1. Two novel qualitative transcriptional signatures robustly applicable to non-research-oriented colorectal cancer samples with low-quality RNA.
Cheng J; Guo Y; Guan G; Huang H; Jiang F; He J; Wu J; Guo Z; Liu X; Ao L
J Cell Mol Med; 2021 Apr; 25(7):3622-3633. PubMed ID: 33719152
[TBL] [Abstract][Full Text] [Related]
2. Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples.
Chen R; Guan Q; Cheng J; He J; Liu H; Cai H; Hong G; Zhang J; Li N; Ao L; Guo Z
Oncotarget; 2017 Jan; 8(4):6652-6662. PubMed ID: 28036264
[TBL] [Abstract][Full Text] [Related]
3. Quantitative or qualitative transcriptional diagnostic signatures? A case study for colorectal cancer.
Guan Q; Yan H; Chen Y; Zheng B; Cai H; He J; Song K; Guo Y; Ao L; Liu H; Zhao W; Wang X; Guo Z
BMC Genomics; 2018 Jan; 19(1):99. PubMed ID: 29378509
[TBL] [Abstract][Full Text] [Related]
4. Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings.
Li M; Li H; Hong G; Tang Z; Liu G; Lin X; Lin M; Qi L; Guo Z
BMC Cancer; 2019 Jan; 19(1):67. PubMed ID: 30642283
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
[TBL] [Abstract][Full Text] [Related]
6. Circumvent the uncertainty in the applications of transcriptional signatures to tumor tissues sampled from different tumor sites.
Cheng J; Guo Y; Gao Q; Li H; Yan H; Li M; Cai H; Zheng W; Li X; Jiang W; Guo Z
Oncotarget; 2017 May; 8(18):30265-30275. PubMed ID: 28427173
[TBL] [Abstract][Full Text] [Related]
7. A qualitative transcriptional signature for the early diagnosis of colorectal cancer.
Guan Q; Zeng Q; Yan H; Xie J; Cheng J; Ao L; He J; Zhao W; Chen K; Guo Y; Guan G; Guo Z
Cancer Sci; 2019 Oct; 110(10):3225-3234. PubMed ID: 31335996
[TBL] [Abstract][Full Text] [Related]
8. Robust transcriptional signatures for low-input RNA samples based on relative expression orderings.
Liu H; Li Y; He J; Guan Q; Chen R; Yan H; Zheng W; Song K; Cai H; Guo Y; Wang X; Guo Z
BMC Genomics; 2017 Nov; 18(1):913. PubMed ID: 29179677
[TBL] [Abstract][Full Text] [Related]
9. Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy.
He J; Cheng J; Guan Q; Yan H; Li Y; Zhao W; Guo Z; Wang X
Cancer Sci; 2020 Jan; 111(1):253-265. PubMed ID: 31785020
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples.
Zhu J; Deane NG; Lewis KB; Padmanabhan C; Washington MK; Ciombor KK; Timmers C; Goldberg RM; Beauchamp RD; Chen X
Sci Rep; 2016 Sep; 6():33273. PubMed ID: 27623752
[TBL] [Abstract][Full Text] [Related]
11. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
[TBL] [Abstract][Full Text] [Related]
12. Gene-expression analysis of a colorectal cancer-specific discriminatory transcript set on formalin-fixed, paraffin-embedded (FFPE) tissue samples.
Kalmár A; Wichmann B; Galamb O; Spisák S; Tóth K; Leiszter K; Nielsen BS; Barták BK; Tulassay Z; Molnár B
Diagn Pathol; 2015 Jul; 10():126. PubMed ID: 26208990
[TBL] [Abstract][Full Text] [Related]
13. A formalin-fixed paraffin-embedded (FFPE)-based prognostic signature to predict metastasis in clinically low risk stage I/II microsatellite stable colorectal cancer.
Low YS; Blöcker C; McPherson JR; Tang SA; Cheng YY; Wong JYS; Chua C; Lim TKH; Tang CL; Chew MH; Tan P; Tan IB; Rozen SG; Cheah PY
Cancer Lett; 2017 Sep; 403():13-20. PubMed ID: 28624625
[TBL] [Abstract][Full Text] [Related]
14. A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients.
Cai H; Guo W; Zhang S; Li N; Wang X; Liu H; Chen R; Wang S; Guo Z; Li J
Breast Cancer Res Treat; 2018 Jul; 170(2):271-277. PubMed ID: 29572677
[TBL] [Abstract][Full Text] [Related]
15. A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources.
Zhao W; Chen B; Guo X; Wang R; Chang Z; Dong Y; Song K; Wang W; Qi L; Gu Y; Wang C; Yang D; Guo Z
Oncotarget; 2016 Apr; 7(14):19060-71. PubMed ID: 26967049
[TBL] [Abstract][Full Text] [Related]
16. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
[TBL] [Abstract][Full Text] [Related]
17. Identification of a five-gene signature with prognostic value in colorectal cancer.
Sun G; Li Y; Peng Y; Lu D; Zhang F; Cui X; Zhang Q; Li Z
J Cell Physiol; 2019 Apr; 234(4):3829-3836. PubMed ID: 30132881
[TBL] [Abstract][Full Text] [Related]
18. Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes.
Wang K; Song K; Ma Z; Yao Y; Liu C; Yang J; Xiao H; Zhang J; Zhang Y; Zhao W
Br J Cancer; 2020 Aug; 123(3):410-417. PubMed ID: 32435058
[TBL] [Abstract][Full Text] [Related]
19. Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis.
Rahman MR; Islam T; Gov E; Turanli B; Gulfidan G; Shahjaman M; Banu NA; Mollah MNH; Arga KY; Moni MA
Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30658502
[TBL] [Abstract][Full Text] [Related]
20. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
